Table 2. The use of LunX mRNA and multiple tumor markers in combination in the diagnosis of lung carcinoma.
| Tumor markers | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|
| LunX mRNA | 50/113 (44.2) | 29/30 (96.67) | 79/143 (55.2) |
| LunX mRNA + CEA | 74/113 (65.5) | 26/30 (86.6) | 100/143 (69.9) |
| LunX mRNA + NSE | 80/113 (70.8) | 25/30 (83.3) | 105/143 (73.4) |
| LunX mRNA + CYFRA21-1 | 85/113 (75.2) | 25/30 (83.3) | 110/143 (76.9) |
| LunX mRNA + CEA + NSE | 93/113 (82.8) | 25/30 (83.3) | 118/143 (82.5) |
| LunX mRNA + NSE + CYFRA21-1 | 97/113 (85.8) | 25/30 (83.3) | 122/143 (85.3) |
| LunX mRNA + CYFRA21-1 + CEA | 101/113 (89.4)* | 25/30 (83.3)# | 125/143 (87.4)* |
| LunX mRNA + CEA + CYFRA21-1 + NSE | 103/113 (91.1)* | 23/30 (76.7)# | 126/143 (88.1)* |
CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 21-1 fragment; NSE, neuron-specific enolase. *, P<0.05, compared with individual test; #, P>0.05, compared with individual test.